WHI Premarin Results Support Short-Term Use; Breast Cancer Reduction May Be Bright Spot
This article was originally published in The Pink Sheet Daily
Executive Summary
Data from the estrogen-only arm of Women's Health Initiative show increased risk of stroke, no effect on heart disease, and a trend towards reduced breast cancer. NIH says the results parallel current clinical recommendations that hormone therapy be used at the lowest dose for the shortest period of time.
You may also be interested in...
Wyeth Launches Prempro DTC Campaign Touting Lowest Treatment Dose
The print ad states that hormone therapy is not a "lifelong commitment." This is Wyeth's first full-scale DTC campaign for hormone replacement therapy since the results of the WHI study were released.
Wyeth Launches Prempro DTC Campaign Touting Lowest Treatment Dose
The print ad states that hormone therapy is not a "lifelong commitment." This is Wyeth's first full-scale DTC campaign for hormone replacement therapy since the results of the WHI study were released.
Wyeth Premarin Memory Data Are Mixed On Dementia Risk; 91% Of Rxs For Vasomotor Relief
Negative safety findings from the Women's Health Initiative have swung Premarin scripts away from most indicated and off-label uses. The WHI Memory Study finds significantly increased risk of dementia when estrogen data are pooled with Prempro, but not among Premarin-only patients alone.